276 related articles for article (PubMed ID: 11461070)
1. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS
Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070
[TBL] [Abstract][Full Text] [Related]
2. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
3. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
Brady MS; Brown K; Patel A; Fisher C; Marx W
Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.
Brady MS; Brown K; Patel A; Fisher C; Marx W
Melanoma Res; 2009 Apr; 19(2):106-11. PubMed ID: 19282789
[TBL] [Abstract][Full Text] [Related]
9. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?
Wu ZY; Smithers BM; Anderson C; Roberts MS
Melanoma Res; 2000 Feb; 10(1):47-54. PubMed ID: 10711640
[TBL] [Abstract][Full Text] [Related]
10. Isolated hyperthermic limb perfusion chemotherapy in Merkel cell tumour: a case report.
Dawson R; Williams OM; Mansel RE
J R Coll Surg Edinb; 1996 Aug; 41(4):255-6. PubMed ID: 8772077
[TBL] [Abstract][Full Text] [Related]
11. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb infusion for advanced soft tissue sarcoma of the extremity.
Moncrieff MD; Kroon HM; Kam PC; Stalley PD; Scolyer RA; Thompson JF
Ann Surg Oncol; 2008 Oct; 15(10):2749-56. PubMed ID: 18648882
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
[TBL] [Abstract][Full Text] [Related]
14. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
15. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics.
Benckhuijsen C; Kroon BB; van Geel AN; Wieberdink J
Eur J Surg Oncol; 1988 Apr; 14(2):157-63. PubMed ID: 3360157
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy.
Roberts MS; Wu ZY; Siebert GA; Anissimov YG; Thompson JF; Smithers BM
Melanoma Res; 2001 Aug; 11(4):423-31. PubMed ID: 11479432
[TBL] [Abstract][Full Text] [Related]
17. Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?
Huismans AM; Kroon HM; Haydu LE; Kam PC; Thompson JF
Ann Surg Oncol; 2012 Sep; 19(9):3050-6. PubMed ID: 22526898
[TBL] [Abstract][Full Text] [Related]
18. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
[TBL] [Abstract][Full Text] [Related]
19. Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity.
Kam PC; Thompson JF
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1039-45. PubMed ID: 20604735
[TBL] [Abstract][Full Text] [Related]
20. Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma.
Elhassadi E; Egan E; O'sullivan G; Mohamed R
Clin Lab Haematol; 2006 Aug; 28(4):279-81. PubMed ID: 16898971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
